Fas and its ligand FasL, members of tumor necrosis factor receptor superfamily, have been implicated in the process of cell apoptosis. FasL consists of two forms, membrane FasL (mFasL) and soluble FasL (sFasL). sFasL can be produced by mFasL cleaved by matrix metalloproteinases (MMP) and also reveals a role for binding to Fas which is expressed on cell surface. Although Fas/FasL axis has been implicated in a variety of diseases, its role in Sjogren's syndrome still remains ill defined. In this study, we investigated the potential of sFasL in the pathogenesis of Sjogren's syndrome (SS). We found that the serum levels of sFasL in SS patients were significantly lower than healthy subjects. Moreover, serum levels of sFasL in patients with mild disease activity were higher than patients with severe disease activity. There is a positive correlation of the serum level of sFasL with uptake index of parotid gland in our expectation. In addition, liver injury involvement in SS patients showed decreased level of sFasL. Furthermore, we here also observed that the protective cytokine IL-10 expression was positively correlated with sFasL expression. Thus, our results here suggest a potential of sFasL in maintaining gland organ homeostasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343225 | PMC |
| http://dx.doi.org/10.1155/2017/5981432 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exogenous binding immunoglobulin protein (BiP) enhance immune regulatory phenotype in ex-vivo Mtb infected PBMCs stratified based on QuantiFERON response.
Cytokine
February 2025
DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Electronic address:
Even though anti-tuberculosis (TB) treatment is readily available, Mycobacterium tuberculosis (Mtb) infection continues to be a global threat with a high death rate recorded from a single infectious agent. This highlights the significance of developing new strategies to curb the growing Mtb infection cases. Host-directed therapies (HDT) offer a promising approach that includes both drug discovery and drug repurposing, aimed at identifying host targets and promoting immune cell populations that can lead to better infection outcomes.
View Article and Find Full Text PDFThe Potential Role of Cell-Death Mechanisms in the Pathogenesis of Familial Mediterranean Fever Attacks: Granzyme A and Beyond.
Diagnostics (Basel)
September 2024
Department of Pediatric Rheumatology, Hacettepe University, 06230 Ankara, Turkey.
Article Synopsis
- - The study focuses on Familial Mediterranean Fever (FMF), an autoinflammatory disease characterized by the activation of the pyrin inflammasome, potentially leading to a specific type of cell death called pyroptosis.
- - Researchers analyzed plasma samples from 25 FMF patients, alongside 10 patients with PFAPA and 10 healthy controls, to investigate the cell-death mechanisms during FMF attacks and the attack-free period.
- - Findings revealed that levels of specific proteins (sFasL and granzyme A) were significantly elevated during FMF attacks but returned to normal when the patient was attack-free, indicating a distinct inflammatory response not seen in the PFAPA group.
Mechano-inhibition of endocytosis sensitizes cancer cells to Fas-induced Apoptosis.
Cell Death Dis
June 2024
Department of Physics, The Ohio State University, Columbus, OH, 43210, USA.
Article Synopsis
- The Fas receptor interacts with its ligand, FasL, to trigger apoptosis, but many cancer cells have low Fas expression, making them resistant to this process.
- Researchers found that blocking endocytosis increases Fas microaggregates on cancer cell membranes, making them more sensitive to Fas-induced apoptosis when treated with a Rho-kinase inhibitor called fasudil.
- The combination of fasudil and soluble FasL effectively inhibited glioblastoma growth in lab models and mice, highlighting the potential of this approach for improving cancer treatments.
Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4.
Int J Mol Sci
October 2023
Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.
TCR-like chimeric antigen receptor (CAR-T) cell therapy has emerged as a game-changing strategy in cancer immunotherapy, offering a broad spectrum of potential antigen targets, particularly in solid tumors containing intracellular antigens. In this study, we investigated the cytotoxicity and functional attributes of in vitro-generated T-lymphocytes, engineered with a TCR-like CAR receptor precisely targeting the cancer testis antigen MAGE-A4. Through viral transduction, T-cells were genetically modified to express the TCR-like CAR receptor and co-cultured with MAGE-A4-expressing tumor cells.
View Article and Find Full Text PDFTCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors.
Biomedicines
October 2023
Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk 630099, Russia.
Adoptive T-cell therapies tailored for the treatment of solid tumors encounter intricate challenges, necessitating the meticulous selection of specific target antigens and the engineering of highly specific T-cell receptors (TCRs). This study delves into the cytotoxicity and functional characteristics of in vitro-cultured T-lymphocytes, equipped with a TCR designed to precisely target the cancer-testis antigen NY-ESO-1. Flow cytometry analysis unveiled a notable increase in the population of cells expressing activation markers upon encountering the NY-ESO-1-positive tumor cell line, SK-Mel-37.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!